QUOTIENT SCIENCES (ALNWICK) LIMITED
Formerly trading as Arcinova, the company is an Alnwick-based biotechnology research and contract manufacturing subsidiary of the private equity-backed pharmaceutical services group Quotient Sciences.
Get an alert when QUOTIENT SCIENCES (ALNWICK) LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Cash
£1.4m
+48.1% vs 2023
Net assets
£18m
-35.8% vs 2023
Employees
186
-11.8% vs 2023
Profit before tax
-£5.4m
-354% vs 2023
Net assets
2-year trend · vs Health Care median
Accounts
2-year trend · Δ = latest vs prior filed period · latest reflected 2024-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 | Δ vs prior |
|---|---|---|---|---|
| Turnover | £17,591,000 | £15,210,000 | -13.5% | |
| Operating profit | -£1,235,000 | -£5,244,000 | -324.6% | |
| Profit before tax | -£1,192,000 | -£5,412,000 | -354% | |
| Net profit | -£1,421,000 | -£7,026,000 | -394.4% | |
| Cash | £917,000 | £1,358,000 | +48.1% | |
| Total assets less current liabilities | £33,964,000 | £28,505,000 | -16.1% | |
| Net assets | £28,610,000 | £18,364,000 | -35.8% | |
| Equity | £28,610,000 | £18,364,000 | -35.8% | |
| Average employees | 211 | 186 | -11.8% | |
| Wages | £8,014,000 | £7,516,000 | -6.2% | |
| Directors' remuneration | — | — | — |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating margin | -7.0% | -34.5% | |
| Net margin | -8.1% | -46.2% | |
| Return on capital employed | -3.6% | -18.4% | |
| Gearing (liabilities / total assets) | 28.0% | 47.1% | |
| Current ratio | 1.67x | 1.75x | |
| Interest cover | -58.81x | -26.89x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Name history
Renamed 3 times since incorporation
- QUOTIENT SCIENCES (ALNWICK) LIMITED 2021-06-28 → present
- ARC TRINOVA LIMITED 2015-12-04 → 2021-06-28
- TRINOVA BIOPHARM LIMITED 2015-11-26 → 2015-12-04
- CROSSCO (1405) LIMITED 2015-09-08 → 2015-11-26
Audit & accounting basis
- Accounting basis
- FRS 101
- Reporting scope
- Standalone (parent only)
- Auditor
- KPMG LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“The Directors have prepared the financial statements on the going concern basis, as they do not intend to liquidate the Company or to cease its operations. They have also concluded that there are no material uncertainties that could have cast significant doubt over their ability to continue as a going concern for at least 12 months from the date of approval of the financial statements.”
Significant events
- “The Company experienced a challenging year in 2024 as revenues were impacted by macro-economic factors associated with the broader life sciences market but, because of significant cost reduction initiatives implemented throughout the period, the Company enters 2025 with a reduced cost structure and a solid base from which to deliver increased revenues and margins going forward.”
- “As part of the Company's ongoing commitment to operational efficiency and margin improvement, a number of targeted cost reduction initiatives were successfully implemented during the year. These actions focused on streamlining support functions, renegotiating key supplier contracts, and simplifying the organisational structure to eliminate duplication and non-essential spending.”
- “The Company continues to make further investments in its facilities to meet the increasing demand for its customers and during 2024 invested £1.2m in capital expenditure projects.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
2 active · 13 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| GLASS, Desmond Kenneth Neil | Director | 2022-05-18 | Nov 1969 | Irish |
| NIEUWENHOVE, Thierry Andre Van | Director | 2023-10-16 | Mar 1973 | Belgian |
Show 13 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| BAGSHAW, Stephen | Director | 2020-07-15 | 2021-02-11 |
| BRYANT, Mark Gunnar | Director | 2018-09-28 | 2021-02-11 |
| CAMERON, Gordon Biggart | Director | 2021-02-11 | 2022-05-18 |
| CHADWICK, Mark Philip, Dr | Director | 2018-07-10 | 2021-02-11 |
| DUNGWORTH, Robert Paul | Director | 2018-07-10 | 2021-02-11 |
| EGERTON, Mark | Director | 2021-02-11 | 2023-10-16 |
| HUDSON, Michael John, Dr | Director | 2018-06-11 | 2019-06-03 |
| JACKSON, Barry William | Director | 2018-06-11 | 2018-09-28 |
| JENKINS, Gareth Nicholas | Director | 2018-07-10 | 2021-02-11 |
| KILBURN, Roger Michael | Director | 2019-09-26 | 2021-02-11 |
| PASS, James Henry | Director | 2015-09-08 | 2015-12-11 |
| RYAN, Paul Christopher | Director | 2015-12-11 | 2021-02-11 |
| SHOTT, Ian Dermot, Doctor | Director | 2015-12-11 | 2021-02-11 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Quotient Sciences Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2021-02-11 | Active |
| Bgf Gp Limited | Corporate entity | Significant influence | 2018-06-11 | Ceased 2021-02-11 |
| Mr Ian Dermot Shott | Individual | Shares 25–50% | 2016-09-06 | Ceased 2021-02-11 |
| Mr Paul Christopher Ryan | Individual | Shares 25–50% | 2016-09-06 | Ceased 2021-02-11 |
Filing timeline
Last 20 of 98 total filings
Material constitutional events — rename, articles re-file, resolution
- 2021-07-12 MA Memorandum articles
- 2021-07-12 RESOLUTIONS Resolution
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2025-09-24 | MR01 | mortgage | Mortgage create with deed with charge number charge creation date | |
| 2025-09-23 | AA | accounts | Accounts with accounts type full | |
| 2025-07-07 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-08-02 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-06-26 | AA | accounts | Accounts with accounts type full | |
| 2023-10-17 | AP01 | officers | Appoint person director company with name date | |
| 2023-10-17 | TM01 | officers | Termination director company with name termination date | |
| 2023-09-04 | AA | accounts | Accounts with accounts type full | |
| 2023-08-14 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-01-20 | CH01 | officers | Change person director company with change date | |
| 2022-09-05 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2022-08-31 | MR01 | mortgage | Mortgage create with deed with charge number charge creation date | |
| 2022-07-29 | AA | accounts | Accounts with accounts type full | |
| 2022-05-20 | AP01 | officers | Appoint person director company with name date | |
| 2022-05-20 | TM01 | officers | Termination director company with name termination date | |
| 2021-09-20 | AA | accounts | Accounts with accounts type full | |
| 2021-09-10 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2021-07-12 | MA | incorporation | Memorandum articles | |
| 2021-07-12 | SH10 | capital | Capital variation of rights attached to shares | |
| 2021-07-12 | RESOLUTIONS | resolution | Resolution |
Public-record activity
Raw counts from Companies House — last 12–24 months